A Phase 4 interventional study of sildenafil and placebo in Erectile Dysfunction, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 31 sites in United States. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2021-02-01.
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies testing sildenafil in Erectile Dysfunction — 1 open to participants now, 1 under way, 1 of them phase 3. sildenafil · Erectile Dysfunction.
Among the 50 studies testing sildenafil in Erectile Dysfunction, this one is the 10th largest by planned enrollment, is one of 5 that started in 2003, is one of 30 in phase 4, and was the 25th registered.
702 studies on the registry are indexed under Erectile Dysfunction; 125 are open to participants now.
Browse Erectile Dysfunction studies →1 of the 50 studies testing sildenafil in Erectile Dysfunction is open now. Recruiting first, the newest first:
sildenafil: first FDA approval 1998 (VIAGRA), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →
Of the 78 Erectile Dysfunction studies recruiting now, 31 (40%) set no upper age limit and 34 (44%) stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.
This study: 21 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
50 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 3 · Phase 3 6 · Phase 4 30
First in 2002; this study’s year is marked. 5 started in 2003.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 300 is above the median of 70 across 551 interventional studies indexed under Erectile Dysfunction.
Median enrollment 108 across the 50 interventional studies. Of the 38 that completed or were terminated, 6 (16%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 50 have an industry lead sponsor. The 10 most frequent:
This study is registered under Pfizer's Upjohn has merged with Mylan to form Viatris Inc., one of the names counted as Viatris Inc.. Under that name alone:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 434 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
27 studies in Erectile Dysfunction by Viatris Inc.: none open now, none under way, none of them phase 3. Of 27 finished, 5 (19%) have results posted.
Among the 27 studies in Erectile Dysfunction by Viatris Inc., this one is the 7th largest by planned enrollment of the 24 interventional ones that give a count, is one of 3 that started in 2003, is one of 19 in phase 4, and was the 16th registered.
Viatris Inc.’s Erectile Dysfunction studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 50 studies testing sildenafil in Erectile Dysfunction, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Viatris Inc.’s 27 in Erectile Dysfunction:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To compare the effects of sildenafil versus placebo on the female partner's sexual satisfaction as assessed by Question 3 of Female Partner of Erectile Dysfunction (ED) Subject Questionnaire (FePEDS-Q): "Over the past 4 weeks, when you had sexual intercourse, how often was it satisfactory for you?" For ED subjects, determine difference in the Erectile Function domain of International Index of Erectile Function (IIEF) between sildenafil citrate and placebo at end of the treatment phase and determine the overall relationship between improved erectile function and increased ED subject and female partner satisfaction.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: sildenafil
Drug: placebo
sildenafil 50 mg (initial dose) tablet by mouth 30 to 60 minutes prior to sexual activity for 12 weeks; depending upon safety, efficacy and tolerability, the dose could be increased to 100 mg or reduced to 25 mg, if necessary.
placebo tablet by mouth 30 to 60 minutes prior to sexual activity for 12 weeks
Question 3 of the Female Partner ED Subject Questionnaire (FePEDS-Q) in female partners.
Time frame: Week 12
International Index of Erectile Function (IIEF) Erectile Function, Desire, Orgasm, Intercourse Satisfaction, and Overall Satisfaction Domains in ED patients
Time frame: Week 8 and Week 12
Self-Esteem and Relationship Questionnaire (SEAR) in ED patients
Time frame: Week 12
ED Subject Event Log in ED patients
Time frame: Week 12
Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) index of treatment satisfaction in ED patients
Time frame: Week 12
Dyadic Adjustment Scale (DAS) in ED patients
Time frame: Week 8 and Week 12
American Urological Association (AUA) Symptom Index in ED patients
Time frame: Week 12
Global Efficacy Assessment Questions (GEQ) in ED patients
Time frame: Week 12
Questions 1 and 2 of Female Partner of ED Subject Questionnaire (FePEDS-Q) in female partners
Time frame: Week 8 and Week 12
Sexual Function Questionnaire (SFQ) Desire, Arousal, Enjoyment and Orgasm Domains in female partners
Time frame: Week 12
Female Sexual Function Inventory (FSFI) Desire, Satisfaction and Arousal Domains in female partners
Time frame: Week 12
Partner EDITS in female partners
Time frame: Week 12
Female Partner Treatment Continuation Question in female partners
Time frame: Week 12
Dyadic Adjustment Scale (DAS) in female partners
Time frame: Week 8 and Week 12
Beck Depression Inventory (BDI-II) in female partners
Time frame: Week 12
Female Partner Event Log in female partners
Time frame: Week 12
AUA Symptom Index in female partners
Time frame: Week 12
The record gives a start of Jun 2003 and a completion of Apr 2004. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sildenafil
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. →